PDCD1 and ovarian carcinoma: This lack of immune activation and response to PD-1 blockade in chemotherapy-resistant ovarian cancer cells were confirmed in the PEO1 and PEO4 cell lines, both of which were established after the patient has relapsed from chemotherapy (Fig. 4b).